APEIRON Biologics AG:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】APEIRON Biologics AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3040)・商品コード:DATA904C3040
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:27
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
APEIRON Biologics AG (APEIRON) is a clinical-stage biotechnology company that concentrates on the development of biological and immunological solutions for the treatment of various cancers. The company’s pipeline products include APN01, APN301, APN311, APN401, APN411, APN421 and APN431. Its APN311 is an antibody-based therapy used for the treatment of high-risk neuroblastoma. APEIRON’s APN301 is an anti-GD2 antibody-IL2 fusion protein used for intratumoral application in GD2+ pediatric cancers. The company carries out projects in biotherapy and cancer immune field. APEIRON is headquartered in Vienna, Austria.

APEIRON Biologics AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
APEIRON Biologics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 10
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 11
Licensing Agreements 12
APEIRON Biologics Enters into Licensing Agreement with Molecular Biotechnology and Medical University of Vienna 12
Apeiron Biologics Enters into Licensing Agreement with Columbia University 13
Apeiron Biologics Enters into Licensing Agreement with Medison Pharma for APN311 14
Apeiron Biologics Enters into Licensing Agreement with Gen Ilac for APN311 15
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 16
Asset Transactions 17
EUSA Pharma Acquires commercialization rights to Isqette from APEIRON Biologics 17
APEIRON Biologics AG – Key Competitors 18
APEIRON Biologics AG – Key Employees 19
APEIRON Biologics AG – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Government and Public Interest 21
Aug 28, 2017: Investment Plan for Europe: EIB grants financing to Apeiron 21
Product News 22
12/18/2017: Apeiron Announces Publication of Clinical Data With Anti-GD2 Antibody Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma 22
10/13/2017: APEIRON Strengthens Management Board with Industry Expert Peter Llewellyn-Davies as New Chief Financial Officer 23
05/09/2017: European Commission approves the only immunotherapy for high-risk neuroblastoma, bringing hope to thousands of children affected by a rare and devastating form of cancer 24
03/27/2017: EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for Dinutuximab Beta for the Treatment of High-risk Neuroblastoma in Europe 25
03/23/2017: APEIRON Biologics Receives CHMP Positive Opinion For Dinutuximab Beta 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Key Facts 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
APEIRON Biologics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
APEIRON Biologics AG, Deals By Therapy Area, 2012 to YTD 2018 8
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 10
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 11
APEIRON Biologics Enters into Licensing Agreement with Molecular Biotechnology and Medical University of Vienna 12
Apeiron Biologics Enters into Licensing Agreement with Columbia University 13
Apeiron Biologics Enters into Licensing Agreement with Medison Pharma for APN311 14
Apeiron Biologics Enters into Licensing Agreement with Gen Ilac for APN311 15
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 16
EUSA Pharma Acquires commercialization rights to Isqette from APEIRON Biologics 17
APEIRON Biologics AG, Key Competitors 18
APEIRON Biologics AG, Key Employees 19

List of Figures
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[APEIRON Biologics AG:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3040)販売に関する免責事項を必ずご確認ください。
★調査レポート[APEIRON Biologics AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆